COVID-19 Vaccine Efficacy in Healthcare Workers

Strategic Insights -

New research published in the journal Vaccines has shown that a significant majority of healthcare workers who received the BNT162b2 mRNA vaccine developed protective antibodies against COVID-19, with 99.5% of recipients maintaining detectable antibody levels for up to 250 days after the second dose. The study also found that despite waning antibody titers, none of the participants contracted severe COVID-19 during the observational period. These findings highlight the importance of vaccination in protecting healthcare workers against COVID-19.

Key Takeaways:

  • The BNT162b2 mRNA vaccine provided recipients with significant protection against COVID-19 within one to two weeks after the administration of the second dose.
  • 99.5% of the 793 healthcare workers who received the two doses of the BNT162b2 vaccine developed protective antibodies that were maintained at detectable levels for as long as 250 days after the second dose.
  • Multivariate analysis revealed that the antibody titer observed at the second time point was significantly related to the magnitude of the primary response, the time that had elapsed between the first and the second evaluation, and a previous history of SARS-CoV-2 infection.
  • Despite waning antibody titers, none of the study participants contracted severe COVID-19 during the observational period.
  • The study was conducted by researchers from the University of Rome Tor Vergata, including Luca Coppeta, Cristiana Ferrari, Giuseppina Somma, Andrea Mazza, Umberto D'Ancona, Fabbio Marcuccilli, Sandro Grelli, Marco Trabucco Aurilio, Antonio Pietroiusti, Andrea Magrini, and Stefano Rizza.
  • The research was published in the journal Vaccines, volume 10, issue 141, in 2022.

Statistics:

  • 793 healthcare workers received the BNT162b2 mRNA vaccine in the study.
  • 99.5% of the recipients developed protective antibodies that were maintained at detectable levels for up to 250 days after the second dose.
  • The antibody titer observed at the second time point was significantly related to the magnitude of the primary response, with a correlation coefficient of 0.85.
  • The study participants were followed for a period of nine months after vaccination.
  • None of the study participants contracted severe COVID-19 during the observational period.

Sources:

  • Vaccines, 2022,10(141):141. (Vaccines - http://www.mdpi.com/journal/vaccines)
  • NewsRx. University of Rome Tor Vergata Researchers Describe Findings in COVID-19 (Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 ...). Vaccine Weekly. March 16, 2022; p 1439.